Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study

Andrea Crosignani, Pier Maria Battezzati, Cristina Cestari, Roberto Stabilini, Dario Conte, Francesco Zappalà, Annarosa Floreani, Giuseppe Montalto, Maurizio Soresi, Alberto Notarbartolo, Elisabetta Buscarini, Luigi Buscarini, Giampiero Buongiorno, Onofrio Giuseppe Manghisi, Mauro Podda

Research output: Contribution to journalArticlepeer-review


Ursodeoxycholic acid (UDCA) improves the biochemical expression of chronic liver disease. Tauroursodeoxycholic acid (TUDCA) was recently shown to have more favourable metabolic properties. We designed a multicenter, randomized, controlled study, aimed at assessing the efficacy of TUDCA for the treatment of chronic hepatitis. One hundred and fifty-five patients with chronic hepatitis were randomly assigned to receive TUDCA at the daily doses of 250, 500 and 1000 mg, or no treatment for 6 months. Aminotransferase and gamma-glutamyl transpeptidase (GGT) serum levels decreased with each dose of TUDCA compared with controls (P <0.001). The 1000 mg dose was followed by more marked improvement compared with 250 mg (P <0.05). A progressive improvement of alanine aminotransferase (ALT) with time (P <0.05) was found only with the two higher doses. TUDCA improves the biochemical expression of chronic hepatitis and daily doses of at least 500 mg are recommended.

Original languageEnglish
Pages (from-to)10-19
Number of pages10
JournalHepatology Research
Issue number1
Publication statusPublished - Dec 1998


  • Bile acids
  • Chronic hepatitis
  • Dose-response relationship
  • Liver disease
  • Tauroursodeoxycholic acid
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A multicentre dose-response study'. Together they form a unique fingerprint.

Cite this